Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The Effect of Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor on Patient-Reported Outcomes: Results from Two 24-Week Phase 2B Dose Ranging Studies Genovese, M. C., Westhovens, R., Kavanaugh, A., Meuleners, L., Van der Aa, A., Harrison, P., Tasset, C. WILEY. 2016
View details for Web of Science ID 000417143405149